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ORIGINAL ARTICLE
Dexamethasone and Salbutamol Stimulate Human
Lung Fibroblast Proliferation
Eran Pickholtz, MD,1 Dan Admon, MD,2 Uzi Izhar, MD,3 Neville Berkman, MBBCh, FRCP,4
and Francesca Levi-Schaffer, RPh, PhD1
Background: Asthma is characterized by bronchial hyperreactivity
and airway remodeling. Subepithelial ﬁbrosis, a feature of remodel-
ing, is accompanied by activation of ﬁbroblasts to myoﬁbroblasts,
with excessive proliferation and increased collagen, extracellular
matrix protein, and proﬁbrogenic cytokine production. Mast cells are
important in the development of asthma and its ﬁbrotic changes.
Objective: In this study, we aimed to investigate the direct effect of
the drugs most frequently used in asthma, that is, glucocorticoste-
roids (dexamethasone) and shortacting b2-agonists (salbutamol), on
human lung ﬁbroblast proliferation when unstimulated or activated
by mast cells or eotaxin.
Methods: Subconﬂuent human fetal lung or bronchial ﬁbroblasts
were incubated with different concentrations of the drugs (24 h) 6
activators, and [3H]-Thymidine was added (24 h) to measure their
proliferation. IL-6 production in the supernatants of conﬂuent mono-
layers cultured in the presence of the drugs or forskolin (24 h) was
analyzed by enzyme-linked immunosorbent assay.
Results: Both drugs alone and in the presence of the activators
enhanced ﬁbroblast proliferation in a seemingly synergistic way for
both fetal and bronchial ﬁbroblasts. Dexamethasone was found to
decrease IL-6 production, while salbutamol increased it.
Conclusions: These observations if corroborated by in vivo data
may possibly account for the deleterious effect of long-term therapy
with b2-bronchodilators and inhaled glucocorticosteroids on the nat-
ural history of asthma.
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Asthma is a chronic inﬂammatory disease characterizedby bronchial hyperreactivity and airway remodeling.
Remodeling features are damage and shedding of airway
epithelium, increased number of goblet cells, mucous gland
hypertrophy, increased ﬁbroblast/myoﬁbroblast numbers, and
increased airway smooth muscle mass and neovascularity.1–3
Fibroblasts are thought to play a major role in the development
of the structural changes in the airways by altering their phe-
notype from a quiescent cell into a-actin containing myoﬁbro-
blasts that display enhanced proliferation, increased collagen
and other extracellular matrix protein production, expression of
adhesion molecules, and production of proﬁbrotic and proin-
ﬂammatory cytokines/chemokines and growth factors.1–4
The early asthmatic response is typically initiated by
activation of tissue-resident mast cells. The subsequent
inﬁltration and activation of several additional inﬂammatory
cells and notably that of the eosinophils account for the late
phase of an asthma attack. Persistence of airway inﬂammation
may explain the chronic disease. We and others have shown
that mast cells and eosinophils are pivotal cells not only in
initiating and maintaining airway inﬂammation in asthma but
also in activation of ﬁbroblasts to become myoﬁbroblasts.5,6
The proﬁbrotic effect of mast cells is due to several mediators,
including histamine, tryptase, IL-6, nerve growth factor,
eotaxin, TGF-b, TNF-a, and others.7–10
Treatment of asthma usually includes short-acting
b2-agonists for the relief of bronchoconstriction and, if
needed, inhaled glucocorticosteroids to treat airway inﬂam-
mation. Glucocorticosteroids have generally been consid-
ered to have antiﬁbrotic activity based on data from
in vitro studies carried out on ﬁbroblasts from different
anatomical origins. However, results obtained with lung
ﬁbroblasts have been inconclusive or contradictory because
some have found that these drugs enhance ﬁbroblast pro-
liferation11–14 and some have shown that they inhibit pro-
liferation and production of proﬁbrotic cytokines.12,15
Moreover, although very effective in reducing airway
inﬂammation, the efﬁcacy of glucocorticosteroids in atten-
uating airway ﬁbrosis is still controversial.16–18 Few studies
have investigated the effect of short-acting b2-agonists
on ﬁbroblast proliferation and also with contrasting
results.19,20 In this study, we were interested to examine
the effect of salbutamol as a paradigm of short-acting
b2-agonists and dexamethasone and as a paradigm of
glucocorticosteroids and their combination on human fetal
lung and adult bronchial ﬁbroblast proliferation by them-
selves and in the presence of mast cells or eotaxin as
stimulators.
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MATERIALS AND METHODS
Fibroblasts
The human fetal lung ﬁbroblast line MRC-5 (American
Type Culture Collection, Manassas, VA) was cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM)/10% fetal
calf serum (FCS) (DMEM supplemented with 10% heat-inac-
tivated FCS, 2 mM L-glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycindall from Biological Industries,
Beit Haemek, Israel) at 378C, 5% CO2, and used for assays
between the second and seventh passages. Human bronchial
ﬁbroblasts were obtained from endobronchial biopsy speci-
mens of normal mucosa from 3 subjects (age, 54–64 yr; 1
female and 2 male subjects not receiving any medications)
undergoing ﬁberoptic bronchoscopy (performed according to
published guidelines) for assessment of contralateral localized
lung cancer, as previously described.8 Informed consent was
obtained. Bronchial ﬁbroblasts were expanded and cultured in
DMEM/10% FCS and passaged weekly by Trypsin-EDTA
(Biological Industries) treatment. They were used for assays
between the second and fourth passages.
Mast Cells and Mast Cell Sonicates
The human mast cell leukemia cell line HMC-1
(donated by Dr J. Butterﬁeld, Mayo Clinic, Rochester, MN)
was used as a source of mast cells.21 HMC-1 cells were
cultured in Iscove’s medium (Biological Industries) supple-
mented with 10% FCS containing Fe [2], 50 U/mL penicillin,
0.05 mg/mL streptomycin, and 160 mL/L (1.2 mM) mono-
thioglycerol. Cells were passaged twice a week.
HMC-1 cells were centrifuged (120g, 5 min) and
resuspended in 2 to 5 mL in DMEM/2% FCS (0.75–1:75 ·
105/mL) and bath sonicated (2 min, 08C; Heat Systems/
Ultrasonic 380W, duty cycle 5 s; output power, 50%). Sonicates
were then microcentrifuged for 5 minutes at 48C, 120g
(Hettich Ultracentrifuge; Hettich Zentrifugen, Tuttlingen,
Germany) to remove cell debris. The debris-free sonicate
supernatant (“sonicate”) was collected into aliquots and
stored at 2808C.
Fibroblast Proliferation Assay
Fibroblast proliferation was assessed using the [3H]-
Thymidine incorporation assay. Fibroblasts were plated in
96-well plates (3–4 · 103 cells per well in 200 mL DMEM/
10% FCS). After incubation for 24 hours, the wells were
rinsed twice with DMEM/2% FCS, and dexamethasone
(Sigma Chemicals, St Louis, MO) (stock solution 1022 M
in ethanol) or salbutamol (stock solution 1024 M in phosphate
buffered saline; Sigma), at different concentrations or mast
cell sonicates (15 · 103), or eotaxin/CCL11 (500 ng/mL)
(R&D, Minneapolis, MN) was added in 200 mL DMEM/
2% FCS in 3 to 4 wells for each treatment. Treatment with
TGF-b (10 ng/mL) (R&D) was used as a positive control.
After an additional incubation for 24 hours, 1 mL of [3H]
Thymidine (2 or 5 mC/well) (DuPont NEN, Boston, MA)
was added to each well, and the cells were incubated for an
additional 24 hours. At the end of the incubation, cells were
washed with cold phosphate buffered saline, ﬁxed with meth-
anol, and precipitated with 5% trichloroacetic acid (Merck,
Darmstadt, Germany). The cells were lysed with 0.1% NaOH,
transferred to scintillation vials, and counted in a b-counter
(LKB 1211 Rackbeta; Pharmacia, Uppsala, Sweden). The
results were obtained as counts per minute per well and are
presented as the percentage of change (increase or decrease)
in the ﬁbroblast proliferation after the treatment compared
with the cells that were incubated with medium alone:
IL-6 Release
To evaluate the presence of IL-6 released in the culture
medium, an ELISA kit (PeptroTech, Rocky Hill, NJ) with
sensitivity of 32 to 2000 pg/mL was used. For these experi-
ments, ﬁbroblasts were cultured in 24-well plates (3 · 103
cells per well in 200 mL DMEM/10% FCS) until conﬂuent.
At this point, the wells were rinsed twice with DMEM/5%
FCS and dexamethasone, salbutamol, or forskolin (stock so-
lution 5 mg/mL in ethanol; Sigma) at different concentrations
was added in 200 mL DMEM/5% FCS. After an 18-hour
incubation, supernatants were collected and kept frozen at
2808C until assayed.
Statistical Analysis
Each experiment was performed in at least triplicates
for 3 or 4 times. The results are presented as the mean 6
standard error of the mean and were analyzed by the unpaired
Student t test or analysis of variance test as appropriate for
each case. P values of ,0.05 were considered signiﬁcant.
RESULTS
Dexamethasone and Salbutamol Increase
Fetal Lung Fibroblast Proliferation Alone
and When Stimulated by Mast Cells
Fetal lung ﬁbroblasts were incubated for 48 hours with
different concentrations of dexamethasone or salbutamol,
and ﬁbroblast proliferation was monitored by [3H]-Thymidine
incorporation (Fig. 1). As shown in Figure 1A, the addition of
dexamethasone caused upregulation in ﬁbroblast proliferation
in the range of concentration between 1028 and 1024 M in
a bell-shaped manner. The maximal effect was achieved with
1026 M (increase in proliferation, 350 6 55%) (P , 0.0001)
and was higher than that obtained with the addition of TGF-b.
Addition of salbutamol (Fig. 1B) also induced increased
ﬁbroblast proliferation, although to a lesser extent than dexa-
methasone. This increase was maximal at 1029 M (187 6
100 ·
Value post incubation with sonicates or drugs or mast cells or drugs and mast cells
Value post incubation with medium alone
:
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31% at 1028 M) and was similar at 1028 and 1027 M. When
dexamethasone and salbutamol were added together at the
same concentration (1025–1028 M), the 2 drugs signiﬁ-
cantly increased ﬁbroblast proliferation in a synergistic fash-
ion (P, 0.0001), with the maximal increase of 4326 30% at
1027 M (Fig. 1C).
Next, we assessed the effect of the drugs on mast cell–
induced ﬁbroblast proliferation. Fetal lung ﬁbroblasts were
preincubated for 30 minutes with either dexamethasone or
salbutamol, and then, mast cell sonicate (15 · 103 cells per
well) was added for further 48 hours. As depicted in Figure 2,
addition of mast cell sonicates increased ﬁbroblast proliferation
FIGURE 1. The inﬂuence of dexamethasone and salbutamol
on fetal lung ﬁbroblast proliferation. Fibroblasts were
incubated for 48 hours with medium alone or with either
dexamethasone (1024–1028 M) (A) or salbutamol (1026–10210 M)
(B) or dexamethasone and salbutamol (1025–1028 M) (C).
TGF-b (10 ng/mL) was used as a positive control. Proliferation
was assessed by [3H]-Thymidine incorporation, as detailed in
Materials and Methods. Data are the mean 6 standard error
of the mean of 4 experiments performed in quadruplicates.
In medium alone, counts per minute of [3H]-Thymidine
incorporation were 474 6 5. *P , 0.05; **P , 0.01;
***P , 0.0001.
FIGURE 2. The inﬂuence of dexamethasone and salbutamol
on mast cell–induced fetal lung ﬁbroblast proliferation.
Fibroblasts were preincubated for 30 minutes with either
dexamethasone (1026–1029 M) (A) or salbutamol (1025–1028
M) (B). Mast cell (HMC-1) sonicates (15 · 103 cells per well)
were then added, and cultures were incubated for further
48 hours. In the control, the ﬁbroblasts were incubated in
DMEM 2% alone or with mast cell sonicates alone. Proliferation
was evaluated as described in the legend to Figure 1. Data
are the mean 6 standard error of the mean of 5 experiments
performed in triplicates. In medium alone, counts per minute
of [3H]-Thymidine incorporation were 219 6 3. **P , 0.01;
***P , 0.0001.
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by 1506 26% (P, 0.05). Preincubation of dexamethasone at
different concentrations further enhanced this effect (Fig. 2A).
The maximal increase in proliferation was observed with
1028 M dexamethasone (3496 43%) (P, 0.0001). A similar
result was obtained when the ﬁbroblasts were incubated with
different concentrations of salbutamol and mast cell sonicates,
that is, salbutamol signiﬁcantly increased ﬁbroblast prolifera-
tion over the effect of the mast cell sonicates alone. The max-
imal increase in proliferation was observed with 1027 M
salbutamol and was 348 6 39% more than the control (P ,
0.0001) (Fig. 2B). In experiments performed with mast cell
sonicate concentrations higher than 15 · 103 cells per well (ie,
with 25 · 103 and 35 · 103 cells per well), still a signiﬁcant
increase in ﬁbroblast proliferation (P , 0.0001) was observed
with both dexamethasone (1026–1029 M) and salbutamol
(1025–1028 M) preincubation.
In Table 1, the results obtained with 1028 M dexameth-
asone and 1027 M salbutamol are depicted. Dexamethasone
at 1028 M enhanced signiﬁcantly by 387 6 41% the ﬁbro-
blast proliferation when preincubated with ﬁbroblasts, there-
after receiving as a trigger 35 · 103 mast cell sonicate per well
with no signiﬁcant increase, however, from lower mast cell
numbers. On the other hand, salbutamol increased in a dose–
response fashion the ﬁbroblast proliferation with increasing
numbers of mast cell sonicates to achieve a maximum of
566 6 76% enhancement with 35 · 103 mast cell per well
at a concentration of 1027 M.
Dexamethasone and Salbutamol Increase
Human Bronchial Fibroblast Proliferation
Alone and When Stimulated by Either Mast
Cells or Eotaxin
When dexamethasone and salbutamol were added
to human bronchial ﬁbroblast subconﬂuent monolayers
(Figs. 3A, B), both drugs caused an increase in ﬁbroblast
proliferation (P , 0.05). Dexamethasone displayed the max-
imal increase at 1028 M (1746 17%) and salbutamol at 1026
M (145 6 16%). Addition of mast cell sonicates (25 · 103
cells per well) alike increased ﬁbroblast proliferation as
expected. Proliferation was further increased when cultures
were preincubated with either dexamethasone or salbut-
amol (Fig. 4A). Cultures preincubated with dexamethasone displayed a signiﬁcant increase in ﬁbroblast proliferation
compared with control and cultures incubated with sonicates
alone. The maximal increase was obtained with 1027 M dexa-
methasone and was 795 6 90% (P , 0.0001). Salbutamol
also increased the proliferative effect of mast cell sonicates
(Fig. 4B). Interestingly, in this case, the inﬂuence of salbuta-
mol was stronger than that of dexamethasone at the same
concentration, and the maximal effect was 1069 6 96%
at 1027 M.
To check whether salbutamol enhances ﬁbroblast pro-
liferation when they are exposed to a deﬁned proﬁbrogenic
compound, eotaxin was added to cultures preincubated with
the drug for 48 hours. Eotaxin by itself increased ﬁbroblast
proliferation by 146 6 9%. When together with salbutamol
(1025–1028 M), a further signiﬁcant increase was detected,
that is, with a maximum of 261 6 18% (P , 0.0001) reached
with salbutamol concentration of 1026 M (Fig. 5).
TABLE 1. Inﬂuence of Mast Cell Numbers on Dexamethasone
and Salbutamol Increase in Fibroblast Proliferation
Mast Cell per Well
Increase in Fibroblast Proliferation (%)
Dexamethasone Salbutamol
15 · 103 349 6 37* 348 6 39*
25 · 103 352 6 36* 405 6 58*
35 · 103 387 6 41* 566 6 76*
Fetal lung ﬁbroblasts were preincubated with either dexamethasone (1028 M) or
salbutamol (1027 M) and then incubated with different concentrations of mast cell
sonicate. Fibroblast proliferation was evaluated and expressed as % increase over the
value obtained with mast cell alone (as described in Materials and Methods). Data are
the mean 6 standard error of the mean of 5 experiments performed in triplicates.
*P , 0.0001.
FIGURE 3. The inﬂuence of dexamethasone and salbutamol
on bronchial ﬁbroblast proliferation. Fibroblasts were
incubated for 48 hours with medium alone or with
dexamethasone (1027–1029 M) (A) or with salbutamol
(1026–1028 M) (B). Data are the mean 6 standard error of
the mean of 2 experiments performed in quadruplicates.
In medium alone, counts per minute of [3H]-Thymidine
incorporation were 270 6 2. *P , 0.05.
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Dexamethasone and Salbutamol Influence
Differently IL-6 Production From Fetal
Lung Fibroblasts
As shown in Figure 6A, dexamethasone decreased in
a dose-dependent fashion IL-6 production by conﬂuent fetal
lung ﬁbroblasts (148% at 1025 M; P , 0.005). Salbutamol in
contrast enhanced this proinﬂammatory cytokine production
also signiﬁcantly with the maximal effect detected at 1025 M
of an increase of 129% (P , 0.01) (Fig. 6B).
Interestingly, when the 2 drugs were added together at
1025 and 1026 M, the inhibiting effect of dexamethasone was
slightly decreased by the addition of salbutamol (not shown).
In a series of experiments (Table 2), salbutamol and forskolin
were compared for their effects on IL-6 production from fetal
lung ﬁbroblasts. Similar increases were detected in IL-6 pro-
duction relative to medium incubated wells. In the presence of
salbutamol at 1027 and 1026 M, the increase in IL-6 found in
the culture medium was 138 6 6%* and 144 6 4%*, respec-
tively, and with forskolin at 1026 and 1025 M, it was 149 6
4%* and 151 6 4%*, respectively (n ¼ 3, *P , 0.05).
DISCUSSION
It is well accepted that there is an increase in the
number of ﬁbroblasts in the airways of patients with asthma
that correlates with thickness of lamina reticularis and disease
severity. Moreover, ﬁbroblast activation and differentiation to
myoﬁbroblasts are also evident.1–4
In the present study, we aimed to investigate the in vitro
effect of glucocorticosteroids and short-acting b2-agonists
widely used as ﬁrst-line antiasthmatic drugs on human lung
ﬁbroblast proliferation and IL-6 production. We speciﬁcally
choose to evaluate ﬁbroblast proliferation because this is the
ﬁrst hallmark of ﬁbrosis taking place. IL-6 was selected
among a plethora of proinﬂammatory proﬁbrotic cytokines
produced by the ﬁbroblast22 that mainly inﬂuences the in-
ﬂammatory response.23,24
We found that dexamethasone and salbutamol alone
and in combination increase both human fetal lung and
human bronchial ﬁbroblast proliferation. Moreover, we
demonstrate for the ﬁrst time that when the ﬁbroblasts are
preincubated with either drug and then with an activator such
as mast cell sonicate or eotaxin, ﬁbroblast proliferation is
further increased. In contrast, the production of the proin-
ﬂammatory and proﬁbrotic cytokine IL-6 by conﬂuent
ﬁbroblast monolayers was found to be decreased by dexa-
methasone, while it was increased in the presence of
FIGURE 4. The inﬂuence of dexamethasone and
salbutamol on mast cell–induced bronchial ﬁbroblast
proliferation. Fibroblasts were preincubated for 30 minutes
with either dexamethasone (1027–1029 M) (A) or
salbutamol (1026–1028 M) (B). Mast cell (HMC-1) sonicates
(15 · 103 cells per well) were then added, and cultures were
incubated for further 48 hours. In the control, the ﬁbroblasts
were incubated in medium alone or with mast cell sonicates
alone. Data are the mean 6 standard error of the mean of
2 experiments performed in quadruplicates. In medium alone,
counts per minute of [H3]-Thymidine incorporation were
270 6 2. ***P , 0.0001.
FIGURE 5. The inﬂuence of salbutamol on eotaxin-induced
bronchial ﬁbroblast proliferation. Fibroblasts were
preincubated with salbutamol (1025–1028 M) for 30 minutes.
Eotaxin (500 ng/mL) was then added to the wells for an
additional 48 hours. In the control, the ﬁbroblasts were
incubated with medium alone or with eotaxin alone. In
medium alone, counts per minute of [H3]-Thymidine
incorporation were 330 6 5. Data are the mean 6 standard
error of the mean of 5 experiments performed in triplicates.
*P , 0.05; **P , 0.01; ***P , 0.0001.
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salbutamol. When the 2 drugs were added together, dexa-
methasone was still able to slightly decrease IL-6 production.
We have previously shown that mast cells enhance
proliferation of human lung ﬁbroblasts, an effect also seen
with histamine and to a lesser extent with tryptase.7 In a more
recent study, we have also deﬁned the proﬁbrotic properties
of eotaxin/CCL11,8 a central mediator of asthma that can also
be produced by mast cells.25
In that study, we did not ﬁnd signiﬁcant differences
between the human fetal lung ﬁbroblast line and human
bronchial ﬁbroblasts regarding their proliferative responses to
eotaxin/CCL11. This was explained by the fact that they were
found to express similar levels of surface CCR3. Similarly, in
the present study, we did not observe signiﬁcant differences
in the response of the fetal lung and the bronchial ﬁbroblasts
toward the proliferative effects of either the drugs or the
stimulants. This is an interesting observation because ﬁbro-
blasts from cell lines and primary cultures might behave
differently. The fact that we did not detect major differences
between these 2 sources of ﬁbroblasts might be due to the fact
that primary cells did not need to be cultured and subcultured
for extensive time and when used were not senescent.
Many studies have been carried out to investigate the
effects of glucorticosteroids on several sources of ﬁbroblasts
such as human fetal lines, or primary human lung, asthmatics
endobronchial biopsies, human nasal polyps derived or
mouse 3T3 and rat lung and even adipose tissue derived
providing sometimes similar and sometimes contrasting
results. We opted for the most commonly used source of
human lung ﬁbroblasts, the cell line MRC-5 and primary
human bronchial ﬁbroblasts.
Regarding our data, it is interesting to note that
generally in the absence of the mast cell sonicate, dexa-
methasone effect was always greater than that of salbutamol.
In this work, we showed for the ﬁrst time that salbutamol
caused a further increase in ﬁbroblast proliferation in a dose-
dependent fashion in ﬁbroblasts treated with eotaxin. This
proliferative event is probably carried out by the interaction
of eotaxin with its receptor and by salbutamol with b2-
receptors.
Glucocorticosteroids in general and speciﬁcally dexa-
methasone are known to decrease gene expression of proin-
ﬂammatory cytokines. Several studies have found that
dexamethasone decreases cytokine secretion by ﬁbroblasts,
among them IL-6.26 The results of our study correlate with
these ﬁndings. But also this decreasing effect is not univer-
sally detected and depends on the exposure duration and the
cytokine under study.27 Studies that tested the effect of
b2-agonists on IL-6 secretion on different cell types found
that these drugs enhanced IL-6 secretion.28 As far as we
know, the effect of b2-agonists on IL-6 secretion from lung
ﬁbroblasts has not yet been studied. We found that salbutamol
increased slightly IL-6 production. Cyclic adenosine mono-
phosphate (cAMP) is known as an IL-6 secretion enhancer
(airway smooth muscle cells, 3T3 ﬁbroblasts, and gingival
TABLE 2. Inﬂuence of Dexamethasone, Salbutamol, and Forskolin on IL-6 Release From Fetal Lung Fibroblasts
Dexamethasone Salbutamol Forskolin
1027 M 1026 M 1025 M 1027 M 1026 M 1025 M 1026 M 1025 M
Change in IL-6 production Y72 6 1%* Y79 6 4%* Y60 6 5%† [138 6 6%* [144 6 4%* [150 6 1%† [149 6 4%* [151 6 4%*
Fibroblasts were incubated with either medium alone (control) or with the indicated concentrations of the compounds, and the change in the IL-6 production was calculated relative




FIGURE 6. The inﬂuence of dexamethasone and salbutamol
on IL-6 production by fetal lung ﬁbroblasts. Fibroblasts were
incubated for 18 hours with medium alone or with medium
with either dexamethasone (1025–1028 M) (A) or salbutamol
(1025–1028 M) (B). IL-6 production was evaluated in the
culture supernatants, as described in Materials and Methods.
Data are the mean 6 standard error of the mean of 2
experiments performed in quadruplicates.
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ﬁbroblasts), even though it has been reported that lung ﬁbro-
blast cell line had an inverse relationship between the amount
of cAMP and the amount of IL-6 secreted from the cell.29
In our study, salbutamol and forskolin that increase
cAMP production, both increased IL-6 secretion from the
ﬁbroblasts. These ﬁndings strengthen the assumption that the
mechanism through which salbutamol affects the increase in
IL-6 secretion is cAMP dependent. Interestingly, when
dexamethasone and salbutamol were added together, the
decrease in IL-6 production was smaller than the one obtained
in the presence of dexamethasone alone.
Many mediators, including growth factors, IL-6, and
other cytokines, are involved in ﬁbroblast proliferation regula-
tion. In a previous study, we found that when added to fetal
lung ﬁbroblasts, IL-6 increased their proliferation up to 140%
(data not published). Therefore, we might speculate that
salbutamol can inﬂuence lung ﬁbroblast proliferation by causing
IL-6 production. The effect of b2-agonists in general and spe-
ciﬁcally of salbutamol on ﬁbroblast proliferation has almost not
been studied. Agarwal and Glasel described the effect of treat-
ment with opioid and b-adrenergic agonists on cell prolifera-
tion.30 They found that although both receptors increase cAMP
production, opioid agonists lowered the level of proliferation,
while a b2-agonist (procaterol) increased cell proliferation.
Silvestri et al20 found that salmeterol decreased fetal lung line
ﬁbroblast proliferation induced by bFGF. The source of the cells
is indeed similar to the cells in our study, but salmeterol is
a long-acting b2-agonist as opposed to salbutamol.
20
Another important difference is that the study by
Silvestri et al,20 and other studies, tested the drug’s effect
on proliferation of cells that were incubated with a growth
factor (in this case basic ﬁbroblast growth factor). It is difﬁ-
cult to determine whether the drug’s effect is independent of
the tested growth factor and whether this can be compared
with our research in which salbutamol’s effect on ﬁbroblasts
was assessed either without additional treatment or in the
presence of mast cells or eotaxin.
It is difﬁcult to speculate how the dexamethasone
carries out its proﬁbrogenic response. Several mechanisms
have been suggested regarding the fashion in which the
glucocorticosteroids enhance ﬁbroblast proliferation. For
example, they can either enhance or decrease the activity of
different growth factors (among them, insulin growth factor-1
and ﬁbroblast growth factor) and their receptors (ie, platelet
derived growth factor11) or their production (ie, connective
tissue growth factor31). The time of drug addition to the cul-
tures can make a difference. When it is added after the cells
reached conﬂuence, it causes enhancement of proliferation,
while drug administration during the exponential growth
phase usually causes a decrease.32 In our protocol, we added
dexamethasone to subconﬂuent monolayer and still it had
a proﬁbrogenic effect.
It is interesting to point out that the literature on the
effect of drug combination on ﬁbroblast proliferation presents
a complex picture. Many researches describe an additive and
a synergistic effect of glucocorticosteroids and b2-agonists.
On the other hand, other studies have found classes of the two
drugs to have antagonistic effects. Peters et al33 reported that
b2-agonists, among them salbutamol, have the ability to
lower the steroid effect on gene transcription by inhibiting
the binding to the glucocorticosteroid responsive element on
the DNA. On the other hand, salbutamol and salmeterol have
been described as having the ability to activate the receptor by
a mechanism related to cAMP increase.34
Our ﬁndings obtained in vitro show that whatever the
underlying mechanism(s) is, the drugs have a direct ﬁbro-
genic effect and a synergistic effect with central players, such
as mast cell–derived mediators in the asthmatic process. If
these in vitro observations are found to be true also in the
in vivo complexity of the asthmatic patient with airway
remodeling and ﬁxed airway obstruction, it is then possible
to speculate that this may not only be part of the natural
course of the disease but a complication of the accepted drug
treatment and a product of the drugs’ interactions with the
inﬂammation mediators. Therefore, if the proﬁbrogenic effect
of glucocorticosteroids and b2-agonists is reconﬁrmed
in vivo, the combination of the remodeling and the drugs’
effect can be dangerous. In conclusion, more in vivo studies
are warranted to clarify what the risks and beneﬁts are of
monotherapy versus combination of inhaled glucocorticoste-
roids and short- and long-acting b2-agonists on airway
remodeling in asthma.
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